PMID: 11926080Apr 3, 2002Paper

Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine

Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
J D VanderkooyR Michael Bagby

Abstract

There is no commonly accepted standard for comparing antidepressant-induced side effects. This study evaluates a clinician-administered scale, the Toronto Side Effect Scale (TSES), in a natural practice clinic. We used the TSES to assess side effects in 193 depression patients who completed 8 weeks of treatment with either bupropion, moclobemide, paroxetine, sertraline, or venlafaxine. Rates of remission (Hamilton Rating Scale for Depression [HRSD] < 7) did not differ across drugs after 8 weeks of treatment. Paired drug comparisons yielded significant differences in 16 of the 32 side effects. We present differences between pairs of the 5 antidepressants in Central Nervous System (CNS), gastrointestinal (GI), and sexual side effects. A measure of side-effect intensity distinguished paroxetine from the other antidepressants on a measure of sexual dysfunction. These results confirm the clinical utility of the TSES as a simple, clinician-administered antidepressant side-effect scale.

References

Apr 1, 1997·Clinical Pharmacology and Therapeutics·J G ModellR L DePalma
Mar 6, 1999·The Journal of Nervous and Mental Disease·M J Dewan, V S Anand
Oct 3, 1999·Journal of Clinical Psychopharmacology·S Vida, K Looper
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON

❮ Previous
Next ❯

Citations

Aug 16, 2003·Journal of Clinical Psychopharmacology·Sophie GrigoriadisR Michael Bagby
Apr 7, 2004·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Nicole L CohenSidney H Kennedy
Jul 3, 2004·Journal of Clinical Psychopharmacology·José Martínez-RagaGaspar Cervera
Jan 12, 2005·Journal of Clinical Psychopharmacology·Sophie GrigoriadisKari Fulton
May 25, 2012·Psychopharmacology·William W StoopsSharon L Walsh
Nov 13, 2002·Pharmacoepidemiology and Drug Safety
Dec 6, 2006·Expert Review of Neurotherapeutics·S R Pandi-PerumalM J Monti
May 27, 2006·Journal of Psychiatric Practice·Stephen R WisniewskiUNKNOWN STARD Investigators
Jul 21, 2006·Journal of Clinical Psychopharmacology·Ophelia Q P YinMoses S S Chow
Dec 17, 2008·Journal of Psychopharmacology·R W Lam
Oct 3, 2013·PloS One·Yevgeny Botanov, Stephen S Ilardi
Nov 30, 2018·The British Journal of Psychiatry : the Journal of Mental Science·Emily IonsonAkshya Vasudev
Sep 17, 2013·Expert Opinion on Drug Safety·Enrico Smeraldi, Dario Delmonte
Aug 1, 2011·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Jieun LeeSang-Hyuk Lee
Sep 6, 2006·International Journal of Impotence Research·R T Segraves
Jul 9, 2014·Obstetrics and Gynecology·Susan D ReedKatherine A Guthrie
Jul 2, 2020·Patient Preference and Adherence·Young Eun MokMoon-Soo Lee
Mar 15, 2006·Expert Review of Neurotherapeutics·Michael E Thase
May 5, 2017·Nordic Journal of Psychiatry·Ülle VõhmaEduard Maron
May 15, 2009·Journal of Clinical Psychopharmacology·Alessandro Serretti, Alberto Chiesa
Apr 25, 2021·BMC Health Services Research·Bettina HabibAllen Huang
Mar 30, 2021·Journal of Clinical Psychopharmacology·Jeffrey J RakofskyBoadie W Dunlop
Jun 16, 2021·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Jaeden ColeAlexander McGirr
Nov 30, 2021·Health Technology Assessment : HTA·Larisa DuffyGlyn Lewis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.